The secret ally: immunostimulation by anticancer drugs
Top Cited Papers
- 3 February 2012
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 11 (3) , 215-233
- https://doi.org/10.1038/nrd3626
Abstract
It has recently become clear that the tumour microenvironment, and in particular the immune system, has a crucial role in modulating tumour progression and response to therapy. Indicators of an ongoing immune response, such as the composition of the intratumoural immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome. Moreover, several anticancer agents — including classical chemotherapeutics and targeted compounds — stimulate tumour-specific immune responses either by inducing the immunogenic death of tumour cells or by engaging immune effector mechanisms. Here, we discuss the molecular and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.Keywords
This publication has 225 references indexed in Scilit:
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survivalThe Journal of Pathology, 2011
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapyCancer and Metastasis Reviews, 2011
- Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cellsCancer Immunology, Immunotherapy, 2010
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationPublished by Elsevier ,2010
- Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinomaInternational Journal of Cancer, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicityThe Prostate, 2009
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006